Abingworth Bioventures 8 closes on $465m
Abingworth has held a final close for its new life sciences fund, Abingworth Bioventures 8 (ABV 8), on its $465m hard-cap, exceeding its $375m target.
More on Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Redalpine expands leadership team amid CHF 1bn-plus fundraise
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds
Iron Wolf Capital targets EUR 70m for second vehicle
Baltic investor anticipates early 2024 launch and will focus on early-stage AI and deeptech startups
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater